The responsibility of Core C, Clinical Production, is to manufacture recombinant antibodies, antibody fragments and immunocytokines of sufficient quantity and purity for the Phase I therapy studies that are the focus of this Program Project. To achieve these goals, Core C has three support functions: 1) Production for clinical trials, 2) Purification for clinical trials and 3) Conjugation and Vialing for clinical trials. The City of Hope has built a $12 million, 20,000 sq. ft., Center for Biomedicine and Genetics (CBG), which houses a pilot Biological Manufacturing Facility operating under current Good Manufacturing Practice (cGMP). The CBG provides Quality Assurance, Quality Control as well as maintenance of the facility. Core C operates within the CBG and has previously produced clinical lots of the chimeric T84.66 antibody, T84.66 minibody, T84.66 diabody and humanized hT84.66-M5A antibody. Standard operating procedures are in place for pilot scale manufacturing at the one to two gram scale. This manufacturing includes generation of a master cell bank, large scale bioreactor production, purification, conjugation if required, and vialing. During this project period, the antibodies proposed for manufacture include the hT84.66-M5A antibody, T84.66-IL2 immunocytokine, and a humanized antibody for pretargeting. In addition the commercial antibodies, Herceptin and Avastin and a hapten for pretargeting will be conjugated with the chelate DOTA. Quality Assurance biosafety release tests of cells, purified bulk and final products are according to the safety guidelines set forth in the FDA

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Sta Maria, Naomi S; Barnes, Samuel R; Weist, Michael R et al. (2015) Low Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells. PLoS One 10:e0142767
Kwok, Cheuk S; Frankel, Paul H; Lopatin, George et al. (2014) Using a single parameter to describe time-activity curves. Cancer Biother Radiopharm 29:83-6
Yazaki, Paul J; Lee, Brian; Channappa, Divya et al. (2013) A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel 26:187-93
Specks, Ulrich; Ikle, David; Stone, John H (2013) Induction regimens for ANCA-Associated Vasculitis. N Engl J Med 369:1865-6
Ng, Thomas S C; Wert, David; Sohi, Hargun et al. (2013) Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101. Clin Cancer Res 19:2518-27
Fonge, Humphrey; Leyton, Jeffrey V (2013) Positron emission tomographic imaging of iodine 124 anti-prostate stem cell antigen-engineered antibody fragments in LAPC-9 tumor-bearing severe combined immunodeficiency mice. Mol Imaging 12:191-202
Povoski, Stephen P; Davis, Paul D; Colcher, David et al. (2013) Single molecular weight discrete PEG compounds: emerging roles in molecular diagnostics, imaging and therapeutics. Expert Rev Mol Diagn 13:315-9
Barat, Bhaswati; Kenanova, Vania E; Olafsen, Tove et al. (2011) Evaluation of two internalizing carcinoembryonic antigen reporter genes for molecular imaging. Mol Imaging Biol 13:526-535
Somlo, George; Spielberger, Ricardo; Frankel, Paul et al. (2011) Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res 17:174-82
Gagnon, Pete; Cheung, Chia-Wei; Lepin, Eric J et al. (2010) Minibodies and Multimodal Chromatography Methods: A Convergence of Challenge and Opportunity. Bioprocess Int 8:26-35

Showing the most recent 10 out of 112 publications